Rheumatology Landing Page

2017 ASPIRE Rheumatology & Inflammatory Bowel Disease Research Awards

This ASPIRE program is part of Pfizer's commitment to supporting research in autoimmune diseases within rheumatology and inflammatory bowel disease.

Mission

The mission of the ASPIRE program is to fund high quality basic science, translational and clinical research through a competitive grants program that advances medical knowledge in the epidemiology, pathogenesis and treatment of selected diseases.

Background

Scientific research continues to advance our knowledge and understanding of autoimmune diseases within rheumatology and inflammatory bowel disease. The 2017 ASPIRE Rheumatology and Inflammatory Bowel Disease Research Awards will fund meritorious research proposals that have the potential to improve patient care.

Areas of Focus

Research areas of interest in rheumatalogic disorders and diseases and inflammatory bowel disease are described below:

General

  • Approaches to improving communication among patients and healthcare providers (e.g., enduring materials, technological advancements, or web-based teaching programs)
  • Health economic and outcomes research related to selected autoimmune diseases
  • Basic research in the etiology of selected autoimmune and inflammatory diseases in rheumatology or gastroenterology.

Rheumatologic Disorders and Diseases
Conditions of interest include, but are not limited to: RA, PsA, SLE, ILD

  • Use of biomarkers in assessment and management
  • Use of ultrasound and magnetic resonance imaging in assessment and management
  • Comorbid conditions, such as diabetes, cardiovascular, pulmonary, or ophthalmologic, and increased risks with concomitant therapies used to treat these comorbidities (including, but not limited to, epidemiology, overlapping pathogenesis, assessment, and management of these conditions)
  • Approaches to improving adherence to therapy
  • Approaches to improving management such as: treating to a specific goal or target by monitoring response and adjusting therapy; evidence-based treatment algorithms; factors predictive of response to therapy
  • Signaling pathways implicated in pathogenesis
  • Kinase inhibitors and other small molecules that are not being studied currently by a company competing with Pfizer Inc

Inflammatory bowel disease

  • Exploration of the role of JAK/STAT pathways in pathogenesis of inflammatory bowel disease
  • Use of biomarkers (of any type) to predict response to treatment, disease course, or to differentiate between Crohn's disease and ulcerative colitis
  • Approaches to improving disease management (e.g. evaluation of sequencing of therapy, treating to a specific goal or target)
  • Approaches to improving adherence to therapy

Available Awards

ASPIRE Rheumatology and Inflammatory Bowel Disease research awards are up to a maximum of $150,000 each. Research projects are expected to complete within 2 years of study start. Larger grants may be considered depending on scope and merit of proposal.